# A 6-Month Extension Study to Assess the Long-Term Safety of Engensis in Amyotrophic Lateral Sclerosis

> **NCT05176093** · PHASE2 · COMPLETED · sponsor: **Helixmith Co., Ltd.** · enrollment: 8 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **BIOLOGICAL:** Engensis
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05176093
- **Lead sponsor:** Helixmith Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-14
- **Primary completion:** 2022-12-29
- **Final completion:** 2024-08-23
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2025-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05176093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05176093, "A 6-Month Extension Study to Assess the Long-Term Safety of Engensis in Amyotrophic Lateral Sclerosis". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05176093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*